Make First Appointment Refer a Patient

Clinical Trials & Research

Home / Clinical Trials & Research / View Open Trials

View Open Trials

Bladder
Breast
Head and Neck
Lung (Non Small Cell)
Lymphomas
Melanoma
Multiple Myeloma
Myelodysplastic Syndrome
Prostate
Renal
Solid Tumors

Bladder

  • 21216 - Ph2 Trila Avel Uro Carcinoma

    A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)(G1T28-209)

  • 20172 - PH 2 Enfortumab in Urothelial Pts

    A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

  • 18095 - NeoAdj Chemo +/- Nivo/IDO1inh MIBC

    A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)

Breast

Head and Neck

Lung (Non Small Cell)

  • 20270 - Ph2 MRTX849 Pembro NSCLC KRAS

    A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

  • 20412 - Ph3 Adj Selp St1B/3 RET+ NSCLC

    A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

  • 20137 - PH3 Atez Tira Dura Sg 3 NSCLC

    GO41854: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)

  • 19043 - Ph2 IMMU-132 met Solid Tumors

    A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)

  • BIODESIX

    Clinical Effectiveness Assessment of VeriStrat© Testing and Validation of Immunotherapy Tests in NSCLC Subjects (INSIGHT)

Lymphomas

Melanoma

Multiple Myeloma

  • 20285 - Ph2 Dara Lena Dexa (DRd) MM I

    A phase II trial of daratumumab, lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Myelodysplastic Syndrome

  • 20178 - Ph3 Vene Aza HR-MDS

    A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Prostate

  • 20248 - PH3 Nirap Abira HRR mCSPC

    A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

  • 19191 - Ph3 Nivo +/- Doce mPC 7DX

    A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CA209-7DX)

  • 19144 - Biomarker DNA Defect Men Prostate

    Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Renal

Solid Tumors